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Abstract 
Objective: LIN28B is a conserved RNA-binding protein critically involved in development, cellular metabolism and 
tumorigenesis. It is frequently overexpressed in human cancers and correlates with tumor aggressiveness as well as 
unfavorable prognosis. However, the expression pattern and oncogenic roles of LIN28B during oral squamous cell 
carcinoma (OSCC) development and progression has not been well established yet. Here, we sought to determine the 
expression of LIN28B and its clinical significance using chemical-induced OSCC animal model, cell lines and primary 
specimens.
Method: The OSCC animal model was induced using 7,12-dimethyl-1,2-bezan-tracene (DMBA) painting in the 
hamster buccal pouch. Buccal lesions from animals were obtained from different time points and subjected to routine 
histological analyses and immunohistochemical staining of LIN28B. The mRNA, protein abundance and subcellular 
localization of LIN28B was determined in a panel of OSCC cell lines by real-time RT-PCR, western blot and immuno-
fluorescence. The expression levels of LIN28B in human primary OSCC samples were further evaluated by immunohis-
tochemical staining. Moreover, the relationship between LIN28B and several clinicopathological parameters as well as 
patients’ prognosis were also assessed.
Results: Our results revealed that negative or low LIN28B expression was commonly observed in normal epithelial, 
whereas more LIN28B abundance was identified in epithelial dysplasia and invasive SCC in the DMBA-induced OSCC 
animal model. Overexpression of LIN28B was identified in a major fraction of OSCC samples(39/58) and significantly 
associated with tumor size (P = 0.049) and advanced clinical stages (P = 0.0286). Patients with increased LIN28B had 
markedly reduced overall survival as compared to those with low LIN28B. Multivariate survival analyses further indi-
cated that LIN28B abundance served as an independent prognostic factor for patients’ overall survival.
Conclusions: Our findings reveal that LIN28B is critically involved in OSCC initiation and progression and aberrantly 
overexpressed in human OSCC. It might represent a novel diagnostic and prognostic biomarker for oral cancer.
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Background
Oral squamous cell carcinoma (OSCC) is one of the com-
mon solid cancers worldwide with well-known etiologic 
factors including smoking abuse, alcohol consumption 
as well as HPV infection, etc. [1]. Despite significant 
progress in the combined and sequential treatment for 
OSCC in the last decades, however, the long-term sur-
vival rate has not been remarkably improved [2]. Much 
efforts have been made to unravel the genetic and epige-
netic abnormalities behind OSCC pathogenesis and ena-
ble us to capture the mechanistic insights into oral cancer 
progression [3]. However, until now, few biomarkers have 
been unequivocally established for diagnostic and prog-
nostic management of oral cancer. This unmet challenge 
significantly impedes the improvement of patients’ treat-
ment outcomes [4]. Therefore, the novel biomarkers dis-
covery and validation is urgent and of great importance 
for early detection, novel therapeutics development, ulti-
mately leading to improved prognosis.
LIN28B and its mammalian homologue LIN28 are 
two RNA-binding protein emerged as key modulators 
for stem cell maintenance, cellular metabolism as well 
as tumorigenesis [5, 6]. LIN28B and LIN28, initially 
identified as key regulators of developmental timing 
in Caenorhabditis elegans, were known as master cell 
reprogramming factors to induce pluripotency in con-
junction with KLF4, OCT4 and Sox2 [7, 8]. Mounting 
evidence has revealed that LIN28B/LIN28 functions as 
negative regulators of microRNA biogenesis, selectively 
represses let-7 family production in diverse physiological 
and pathological settings, although they act in different 
ways [9]. Moreover, they have been implicated in tumori-
genesis and usually aberrantly overexpressed in multiple 
human cancers including hepatocellular, colon, intestinal 
and head neck cancers. Their overexpression commonly 
associated with tumor aggressive behaviors, advanced 
clinicopathological features, and decreased survival 
[10–13]. Gain-and loss-of-function studies have further 
revealed that LIN28B/LIN28 promotes cancer cell prolif-
eration, invasion and metastasis both in vitro and in vivo 
largely through let-7 repression [10, 12, 14]. Noticeably, 
comprehensive analyses of LIN28 and LIN28B expres-
sion in human cancers pointed to LIN28B as the more 
relevant homologue underlying tumorigenesis [15]. Fur-
ther evidence linking LIN28B to tumorigenesis derived 
from several previous findings that it facilitated cellular 
malignant transformation in vitro [14–16] and transgenic 
overexpression was sufficient to initiate neuroblastoma 
and hepatoblastoma and also required for their mainte-
nance in murine models [11, 17]. Moreover, conditional 
LIN28B deletion or siRNA-mediated LIN28B knock-
down reduced tumor burden, inhibited metastasis and 
prolonged survival in  vivo [10, 18]. Collectively, these 
findings have provided strong evidence that LIN28B is 
a bona fide oncogene mediating cancer initiation and 
progression, and also a novel therapeutic target against 
cancer.
Accumulating evidence has revealed essential clues 
regarding LIN28B expression and potential roles in oral 
cancers [19, 20]. We have revealed a functional single 
nucleotide polymorphism [variant allele (T) of rs221636] 
in LIN28B,which is significantly associated with oral 
cancer susceptibility in a Chinese population, thus sup-
porting the key roles of LIN28B during oral tumorigen-
esis [21]. However, the expression pattern of LIN28B 
and its clinicopathological significance in OSCC have 
not been definitively established yet. In the present 
study, we sought to determine the LIN28B expression in 
OSCC cell line, animal model and primary human OSCC 
specimens, and further identify potential relationships 
between its abundance and clinicopathological features 
as well as patients’ prognosis.
Methods
Cell lines and chemicals
A panel of human OSCC cell lines including HN4, HN6, 
Tca8113, Cal27, SCC9, and SCC25 were utilized here. 
HN4, HN6, Tca8113 and human immortalized oral epi-
thelial cells (HIOEC) were gifts from Prof. Wantao Chen 
(Shanghai Jiaotong University) [22]. The Cal27, SCC9 
and SCC25 were commercially purchased from Ameri-
can Type Culture Collection (ATCC). HIOEC was grown 
in EpiLife medium (Life technologies) with the addition 
of human keratinocyte growth supplement (Life tech-
nologies). All cancerous cell lines were grown in DMEM/
F12 (Life technologies) supplemented with 10  % FBS 
(Hyclone) and penicillin and streptomycin (100 units/
ml), and maintained in a humidified incubator with 5 % 
CO2 at 37 °C.
The carcinogenic chemical polycyclic aromatic hydro-
carbon 7,12-dimethyl-1,2-bezan-tracene (DMBA) was 
purchased from Sigma Aldrich (D3254) and dissolved 
in mineral oil. Other chemical agents were all purchased 
from Sigma Aldrich unless otherwise stated.
Chemical‑induced buccal OSCC animal model
The DMBA-induced hamster buccal pouch squamous 
cell carcinogenesis model was performed with minor 
modifications as described before [23, 24]. This animal 
experimental protocol was institutionally approved and 
conducted in accordance with the Institutional Guide 
for the Care and Use of Animals. Briefly, forty Syrian 
golden hamsters (male, 6–8  weeks old, approximately 
100–120  g weight) were purchased from Shanghai 
Laboratory Animal Center, and then randomly divided 
into three experimental and one control groups (10 
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animals per group). After environment acclimatization 
for 1  week, left pouches of animals in the experimental 
groups were painted with 0.5 % DMBA solution using a 
No. 4 sable-hair brush on every Monday, Wednesday and 
Friday for consecutive 16  weeks. The control hamsters 
were received vehicle only in the similar way. At these 
following time points (4, 10, 16 weeks), the animals were 
sacrificed and left buccal pouches were harvested and 
processed as scheduled.
Cell immunofluorescence assay
For cellular immunoflurescent staining assay, single cells 
were pre-seeded and grown on glass coverslips overnight, 
then fixed with 4  % paraformaldehyde and permeabi-
lized in 0.1 % Triton X-100 and sequentially treated with 
3 % BSA and primary antibody against LIN28B (Abcam, 
ab71415, 1:100 dilution). Following overnight incubation, 
these cells were further incubated with appropriate sec-
ondary antibody and cytoskeleton actin/nuclear DAPI 
staining. Immunofluorescence was visualized under a 
Zeiss fluorescence microscope and image-captured using 
the same parameters.
RNA extraction and real time RT‑PCR
Total RNA was extracted from cells with Trizol (Life tech-
nologies) reagent and then subjected to RT-PCR reactions 
using PrimeScript™ RT-PCR kit (Takara) on a LightCycler 
96 device (Roche) as described previously [25]. The gene-
specific primers for human LIN28B and GAPDH were 
used as follows: LIN28B Forward: GCACATTAGAC-
CATGCGAGC; Reverse: CTTTGCTAGCCCCGCCTTC; 
GAPDH Forward: AGGTGAAGGTCGGAGTCAAC; 
Reverse: AGTTGAGGTCAATGAAGGGG. Relative 
mRNA expression was quantified using comparative CT 
method as compared to GAPDH.
Protein extraction and western blot
Cells were lysed with ice-cold RIPA buffer supplemented 
with the protease inhibitor cocktail (Roche). Lysates 
were resolved by SDS-PAGE, and transferred onto PVDF 
membranes (Bio-Rad). After incubation with primary 
antibodies (LIN28B, Abcam, ab71415, 1:1000 dilution; 
GAPDH, Abcam, ab37168, 1:2000 dilution) overnight, 
these blots were detected with appropriate secondary 
antibodies (Life technologies) and visualized by enhanced 
chemiluminescence (Pierce). The relative levels of each 
protein were determined with Image J software and com-
pared as appropriate.
Patients and tissue specimens
A cohort of 58 patients with primary OSCC receiving 
surgical treatment at our hospital from January 2007 to 
December 2012 were enrolled. This study protocol was 
reviewed and approved by the University Research Ethic 
Committee. Written informed consent was obtained 
from these patients. Patient inclusion criteria were 
listed as follows: (1) primary OSCC without any prior 
therapy; (2) patients underwent extensive tumor resec-
tion and neck dissection; (3) detailed information avail-
able including clinical, pathological and follow-up data. 
The archived H&E slides were retrieved and further 
analyzed to verify previous diagnoses. Eighteen normal 
oral mucosa were obtained from other non-cancer sur-
geries and histologically confirmed. Three paired fresh 
OSCC as well as adjacent healthy mucosa samples were 
obtained within 30  min after surgical resection and 
snap-frozen in liquid nitrogen and then stored under 
−80 °C until use.
Histopathological evaluation and immunohistochemistry
The relevant clinicopathological parameters including 
histological grade, clinical stage, TNM classification, etc. 
were determined as described before [25, 26]. Immuno-
histochemical staining for LIN28B was performed on 
formalin-fixed, paraffin-embedded tumor specimens. 
Briefly, tissue sections from representative paraffin blocks 
were deparaffinised and rehydrated. Antigens retrieval 
was performed in microwave heating in citrate buffer 
(10  mmol/L, pH 6.0) for 20  min. These slides were fur-
ther incubated with primary antibodies (LIN28B, Abcam, 
ab71415, 1:200 dilution) overnight and developed with 
3,3′-diaminobenzidine and counterstained with hema-
toxylin. Negative controls (without primary antibody 
incubation) were included in each staining run. LIN28B 
immunoreactivity was evaluated independently by oral 
pathologists without knowledge of clinical data.
LIN28B immunoreactivity in both animal and human 
samples was semi-quantitatively evaluated according 
to staining intensity and distribution using the immu-
noreactive score which was calculated as intensity 
score × proportion score as we reported previously [25–
27]. Intensity score was defined as 0, negative; 1, weak; 
2, moderate; 3, strong. The proportion score was graded 
as 0, negative; 1, <10 %; 2, 11–50 %; 3, 51–80 %; 4, >80 % 
positive cells. LIN28B immunoreactivity in tissue sam-
ples was categorized into three subgroups based on the 
final scores: 0, negative; 1–4, low expression; 4–12, high 
expression.
Statistical analysis
The quantitative data was shown as mean ±  SD of two 
or three independent experiments and compared with 
Student’s t test or ANOVA. The associations between 
LIN28B abundance and clinicopathological parameters 
were evaluated using Fisher exact test. The overall sur-
vival rates were estimated using Kaplan–Meier method 
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and compared with Log-rank test. The Cox proportional 
hazards model was applied to assess the impact of vari-
ous clinicopathological parameters on patients overall 
survival. P values less than 0.05 (two-sides) were consid-
ered statistically significant.
Results
The expression pattern of LIN28B in DMBA‑induced buccal 
OSCC animal model
We have provided strong evidence that the functional 
SNP (rs221636) in LIN28B gene contributes to oral can-
cer susceptibility in a Chinese population [21]. However, 
the oncogenic roles of LIN28B during oral cancer initia-
tion and propagation in vivo have not yet been well estab-
lished. To address this, we developed the hamster buccal 
pouch carcinogenesis model by chemical agent DMBA, 
which is a popular animal model for OSCC. Gross 
examinations of hamster buccal pouches following ani-
mal euthanization revealed no apparent changes in min-
eral oil-treated control animals, while thickened mucosa 
with rough surface was observed in 4- and 10-week 
DMBA-treated animals. Exophytic tumor-like or ulcer-
like lesions were frequently visible in 16-week DMBA-
treated animals. The histopathological analyses further 
confirmed the multiple pathological stages induced by 
DMBA such as epithelial dysplasia and invasive squa-
mous cell carcinoma (Fig. 1a, c, e). Therefore, this animal 
model closely recapitulated the typical multiple stages of 
OSCC, reminiscence of human OSCC tumorigenesis [24]. 
We next determined the expression pattern of LIN28B 
in samples from this animal model. As shown in Fig. 1b, 
d, f, immunohistochemical staining of LIN28B in buccal 
samples from diverse stages of disease indicated nega-
tive in most normal epithelial but significantly higher in 
epithelial dysplasia and invasive carcinoma. Furthermore, 
our immunohistochemistry data (Table  1) revealed that 
LIN28B is overexpressed in the majority of SCC samples, 
while much less in samples with dysplasia and normal epi-
thelial. Together, these data indicate that LIN28B might 
be critically involved in OSCC development and func-
tions as a oncogenic driver behind oral tumorigenesis.
Expression and localization of LIN28B in OSCC cell lines
To delineate the expression of LIN28B in human OSCC, 
both mRNA and protein abundance of LIN28B in a panel 
of OSCC cell lines were measured as compared to the 
immortalized oral epithelial cell line HIOEC. The real-
time RT-PCR data revealed significantly increased LIN28B 
transcripts in all cancerous cells in relative to HIOCE 
(Fig.  2a). The western blot results further indicated 
remarkably upregulated LIN28B protein in all OSCC cell 
lines examined (Fig. 2b). In addition, Lin28B protein was 
pronouncedly increased in oral cancer tissues compared to 
the pair-matched adjacent non-cancerous tissues (n =  3) 
(Fig. 2c). We next performed cellular immunofluorescence 
assay in three selected cell lines to visualize the subcellular 
Fig. 1 LIN28B expression in DMBA-induced OSCC animal model. a, b H&E staining and LIN28B immunohistochemical staining of normal buccal 
epithelial in control animals; c, d H&E staining and LIN28B immunohistochemical staining of epithelial dysplasia in experimental animals; e, f H&E 
staining and LIN28B immunohistochemical staining of squamous cell carcinoma in experimental animals. Scale bar 50 μm
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localization of LIN28B in OSCC. As displayed in Fig.  3, 
the LIN8B protein was mainly identified in nucleus, while 
much less in cytoplasm in OSCC cells.
Clinicopathological characteristics and LIN28B expression 
in primary OSCC patients
To further examine LIN28B expression in clinical speci-
mens and clinicopathological significance, we evaluated 
the expression level of LIN28B by immunohistochemical 
staining in a retrospective cohort of 58 primary OSCC 
patients. The epidemiologic information and clinico-
pathological parameters of these patients were listed in 
Table 2. In brief, 37 males and 21 females were enrolled 
with mean age 46.3  years. The follow-up durations 
ranged from 3 to 66 months (average 27.4 months).
As shown in Fig. 4c, LIN28B positive staining was iden-
tified in nucleus or both nucleus and cytoplasm in can-
cer specimens, whereas weak or negative staining was 
detected in the normal counterparts. Based on our immu-
nohistochemistry scoring regime, LIN28B abundance 
in these primary OSCC and healthy oral epithelial was 
further categorized. As shown in Table  3, LIN28B levels 
in these OSCC sample can be graded as low (19) or high 
expression group (39), while negative (4), low expres-
sion (12) and high expression (4) in normal oral mucosa 
samples, thus indicating that LIN28B was aberrantly 
overexpressed in a fraction of oral cancers. The detailed 
relationships between LIN28B abundance and clinico-
pathological parameters were further shown in Table  2. 
There were no significant correlations found between 
LIN28B and patient age, gender, histopathological grade 
and clinical stage. Notably, LIN28B abundance was found 
to be associated with tumor size and cervical lymph nodes 
metastasis with P value 0.049, 0.0286, respectively.
LIN28B expression levels associated with OSCC patients’ 
overall survival
To further reveal prognostic values of LIN28B expres-
sion in OSCC patients, we next aimed to identify pos-
sible relationship between its expression and clinical 
outcomes. Until the last follow-up, 35 of 58 (60.3  %) 
patients remained alive and also disease-free, 6 (10.3 %) 
still alive but with local recurrences and/or cervical nodal 
metastases, whereas 17 (29.4 %) died due to post-surgical 
relapse, metastases or other diseases. The Kaplan–Meier 
survival analyses revealed that high LIN28B had adverse 
prognostic impact for patients’ outcomes. High LIN28B 
expression in OSCC significantly associated with short 
overall survival as compared to its low counterparts 
(Log-rank, P = 0.0386, Fig. 5).
To further assess prognostic values of LIN28B abun-
dance for OSCC patients, both univariate and multi-
variate survival analyses were performed using Cox 
proportional hazards regression model. The univariate 
survival analysis identified no clinicopathological vari-
ables as key factors significantly affecting patients overall 
survival (Table 4). Multivariate survival analysis revealed 
that LIN28B expression status was a critical independent 
prognostic marker for overall survival of OSCC patients 
(P  =  0.043, Table  4). Together, these data reveal that 
LIN28B can serve as an important prognostic biomarker 
for OSCC.
Table 1 LIN28B expression in  the DMBA-induced buccal 
pouch squamous cell carcinogenesis model
Lesion/
total
LIN28B expression p values
Negative Low High
Normal mucosa 10/10 7 2 1 0.0328
Dysplasia 9/10 5 3 1
Squamous cell  
carcinoma
10/10 1 3 6
Fig. 2 LIN28B expression in human OSCC cell lines and paired 
samples. a LIN28B mRNA levels in a panel of OSCC cell lines and 
HIOEC were measured by real time RT-PCR. b LIN28B protein levels in 
a panel of OSCC cell lines and HIOEC were measured by western blot. 
c LIN28B abundance in three pairs of OSCC and matched adjacent 
non-cancerous epithelial was compared by western blot. Data shown 
here are mean ± SD from three independent experiments, *P < 0.05, 
**P < 0.01, ANOVA and Student t analyses
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Discussion
Accumulating evidence has revealed that the pluripo-
tency factor LIN28B, a highly conserved RNA-binding 
protein, has emerged as a key player in many develop-
mental and pathological processes including stem cell 
hemostasis, cellular metabolism and tumorigenesis [15, 
28, 29]. Of great interests, it has been found to medi-
ate cellular malignant transformation, fuel cancer cell 
Fig. 3 LIN28B expression in human OSCC samples measured by immunohistochemical staining. a Representative negative staining of LIN28B in 
normal oral epithelial; b Representative low expression of LIN28B in a primary human OSCC sample; c Representative high expression of LIN28B in a 
primary human OSCC sample. Nuclei are counterstained with hematoxylin. Scale bar 100 μm
Table 2 LIN28B expression pattern in  OSCC and  normal 
oral mucosa
LIN28B expression p values
Negative Low High
Normal oral mucosa 5 10 3 <0.0001
OSCC 0 19 39
Fig. 4 LIN28B subcellular distribution in OSCC cells determined by immunofluorescence. LIN28B is mainly identified in nucleus, less in cytoplasm in 
three OSCC cell lines. Nuclei and cytoplasm are counterstained with F-actin and DAPI, respectively. Scale bar 50 μm
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proliferation, invasion and metastasis cascade as well as 
promote cancer stem cell maintenance in diverse human 
cancers [6, 10, 14]. Its overexpression significantly associ-
ated with cancer aggressiveness and poor prognosis [14, 
15]. These findings indicate that LIN28B is an bona fide 
oncogene that might be exploited as cancer biomarker 
and therapeutic target. Here, we measured the expression 
patterns of LIN28B in OSCC cells, chemical-induced 
OSCC animal model and primary OSCC samples, and 
further determined its clinicopathological significance. 
Our findings reveal that LIN28B might be involved in 
OSCC initiation and progression by serving as an onco-
gene. Its overexpression associates with aggressive 
clinicopathological features and unfavorable patients’ 
prognosis in a significant fraction of OSCC.
The human oral tumorigenesis is characterized by 
multiple and consecutive histopathological stages from 
normal epithelial to invasive SCC driven by oncogenes 
activation and tumor suppressor inactivation [30]. This 
has been elegantly reproduced in chemical-induced 
animal models, such as DMBA-induced buccal SCC in 
hamster and 4-nitroquinoline 1-oxide (4NQO)-induced 
oral SCC in rodents [23, 24, 31]. In the present study, 
we utilized the former model and determined LIN28B 
expression during OSCC tumorigenesis by immuno-
histochemistry. As anticipated, our findings established 
that LIN28B expression was almost negative in normal 
epithelial, but its positive staining gradually became 
more and more in dysplasia and SCC samples, suggest-
ing that LIN28B served as an oncogene critically involved 
in OSCC pathogenesis. This is well consistent with the 
oncogenic roles of LIN28B driving cancer initiation [11]. 
Because a line of evidence has revealed that LIN28B 
alone is capable to induce cell transformation in vitro and 
sufficient to initiate multiple cancers in vivo [11, 15–17]. 
Collectively, our data provide the in vivo evidence to sup-
port the oncogenic roles of LIN28B in oral tumorigen-
esis. Of course, further in-depth investigations into the 
detailed mechanism regarding LIN28B behind OSCC are 
warranted in future.
Previous findings have indicated that LIN28B is usu-
ally overexpressed in a broad spectrum of human can-
cers and is critically required for cancer overgrowth [15, 
18]. Importantly, overexpression of LIN28B significantly 
associated with advanced stages, lymph node metastasis 
and unfavorable prognosis in diverse cancers including 
oral cancer [18, 20]. For example, Wu and his colleague 
reported that LIN28 and LIN28B expression levels were 
both increased in 72 primary OSCC and positively cor-
related with gender, tumor differentiation and patients’ 
survival [20]. Consistently, our data further extended 
these previous findings and determined LIN28B abun-
dance in a panel of OSCC cell lines and an independ-
ent cohort of primary OSCC. Our results revealed that 
Lin28B was abnormally overexpressed in OSCC cells 
and human samples. Noticeably, elevated LIN28B sig-
nificantly associated with tumor size and advanced clini-
cal stages, but not the gender and tumor differentiation 
status as reported by Wu [20]. We reasoned that this 
Table 3 Associations between LIN28B expression and mul-
tiple clinicopathological parameters in primary OSCC
Clinicopathological parameters Cases LIN28B p values
Low High
Gender 58 19 39
 Male 37 12 25 1.000
 Female 21 7 14
Age
 ≤60 30 13 17 0.0973
 >60 28 6 22
Tumor size
 T1–T2 31 14 17 0.0490
 T3–T4 27 5 22
Pathological grade
 I 33 12 21 0.5794
 II–III 25 7 18
Cervical node metastasis
 N(0) 30 12 18 0.2708
 N(+) 28 7 21
Clinical stage
 I–II 16 9 7 0.0286
 III–IV 42 10 32
Fig. 5 Kaplan–Meier graphs representing the probability of cumula-
tive overall survival in OSCC patients based on LIN28B expression. 
High LIN28B expression significantly associated with reduced overall 
survival in OSCC patients. These survival analyses were estimated by 
Kaplan–Meier method and compared with Log-rank test
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discrepancy might be due to inherent tumor heteroge-
neity and different immunohistochemical scores and 
patient stratification. Interestingly, when the manuscript 
was in preparation, Lin and his colleague reported that 
elevated LIN28B correlated with lymph node metastasis 
in OSCC, although the mRNA abundance of LIN28B was 
utilized as readout by quantitative real-time PCR assay in 
20 paired samples [32]. Therefore, our findings together 
with others strongly support the notion that LIN28B is 
aberrantly overexpressed in OSCC and significantly cor-
related with malignant clinicopathological features.
Although past decades have witnessed much progress 
in diagnosis and treatment for OSCC, however, the long-
term survival still remains disappointing. Accurate prog-
nostic prediction regime for OSCC is a great challenge, 
but highly beneficial in the clinic. Evidence has suggested 
that LIN28B may function as a key prognostic predictor 
for patients with colon, oesophagus cancer and neuro-
blastoma [17, 18, 33]. Indeed, our results indicated that 
high LIN28B correlated with decreased patients’ survival 
and served as an independent prognostic factor affecting 
patients’ survival. This finding is in agreement with pre-
vious report where they showed that patients with high 
LIN28B had earlier recurrence and decreased overall sur-
vival rates [20]. Thus, these data indicate that the expres-
sion status of LIN28B might serve as not only a novel 
diagnostic, but also a prognostic biomarker for OSCC. 
However, a large cohort of patients with long-term fol-
low-up is still needed to definitively establish the prog-
nostic values of LIN28B for OSCC.
In conclusion, our findings reveal that LIN28B might 
be critically involved in OSCC initiation and progression. 
Its upregulation correlates with aggressive clinicopatho-
logical parameters and adverse prognosis, thus suggest-
ing that LIN28B might serve as a novel cancer biomarker 
as well as therapeutic target for OSCC.
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